专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120157335A1 Flap Endonuclease-1 As A Marker For Cancer 审中-公开
标题翻译：瓣内切核酸酶-1作为癌症的标志物
公开(公告)号：US20120157335A1
公开(公告)日：2012-06-21
申请号：US13351801
申请日：2012-01-17
申请人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
发明人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
IPC分类号： C40B30/04 , G01N33/573 , C40B40/10 , G01N33/574 , C07K16/40
CPC分类号： G01N33/573 , G01N33/54306 , G01N33/57411 , G01N33/57415 , G01N33/57419 , G01N33/57423 , G01N33/5743 , G01N33/57434 , G01N33/57438 , G01N33/57442 , G01N33/57449 , G01N33/57488 , G01N2333/922 , G01N2800/52 , G01N2800/7028 , G16H50/30 , Y02A90/26
摘要： Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.
摘要翻译：提供了帮助评估癌症的方法，包括使用Flap核酸内切酶-1蛋白（= FEN1）作为不同癌症类型的通用标记。特别地，公开了从样品中得到的来自个体的液体样品中评估癌症的方法，其包括测量样品中的FEN1。 FEN1的测量可用于癌症的早期检测或用于手术切除肿瘤的患者的监测。

2. 发明授权

US09518990B2 Secernin-1 as a marker for cancer 有权
标题翻译： Secernin-1作为癌症的标志物
公开(公告)号：US09518990B2
公开(公告)日：2016-12-13
申请号：US13272399
申请日：2011-10-13
申请人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
发明人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Riedlinger , Markus Roessler , Michael Tacke
IPC分类号： G01N1/00 , G01N33/00 , G01N33/48 , G01N33/50 , G01N33/53 , G01N33/574
CPC分类号： G01N33/57484
摘要： Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：披露了一种有助于评估癌症的方法。它涉及使用Secernin-1蛋白（SCRN1）作为不同癌症类型的通用标记物。更具体地公开了通过测量样品中的SCRN1来从源自个体的液体样品中评估癌症的方法。 SCRN1的测定可以例如用于癌症的早期检测或者进行手术的患者的监视。

3. 发明申请

US20120028835A1 SECERNIN-1 AS A MARKER FOR CANCER 有权
标题翻译： SECERNIN-1作为癌症标记
公开(公告)号：US20120028835A1
公开(公告)日：2012-02-02
申请号：US13272399
申请日：2011-10-13
申请人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Kloeckner , Markus Roessler , Michael Tacke
发明人： Norbert Wild , Marie-Luise Hagmann , Johann Karl , Julia Kloeckner , Markus Roessler , Michael Tacke
IPC分类号： C40B30/04 , C40B40/10 , G01N33/574
CPC分类号： G01N33/57484
摘要： Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：披露了一种有助于评估癌症的方法。它涉及使用Secernin-1蛋白（SCRN1）作为不同癌症类型的通用标记物。更具体地公开了通过测量样品中的SCRN1来从源自个体的液体样品中评估癌症的方法。 SCRN1的测定可以例如用于癌症的早期检测或者进行手术的患者的监视。

4. 发明申请

US20070184498A1 Protein RS15A as a marker for colorectal cancer 审中-公开
标题翻译：蛋白质RS15A作为结肠直肠癌的标志物
公开(公告)号：US20070184498A1
公开(公告)日：2007-08-09
申请号：US11640520
申请日：2006-12-15
申请人： Michael Tacke , Marie-Luise Hagmann , Johann Karl , Michael Pfeffer , Herbert Andres , Michael Thierolf , Norbert Wild , Werner Zolg
发明人： Michael Tacke , Marie-Luise Hagmann , Johann Karl , Michael Pfeffer , Herbert Andres , Michael Thierolf , Norbert Wild , Werner Zolg
IPC分类号： G01N33/574
CPC分类号： G01N33/57419
摘要： The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein RS15A (ribosomal protein S15a) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring RS15A in said sample. Measurement of RS15A can, e.g., be used in the early detection or diagnosis of colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的诊断。它公开了蛋白质RS15A（核糖体蛋白S15a）在结直肠癌诊断中的应用。本发明涉及通过在所述样品中测量RS15A从个体衍生的来自液体样品的结肠直肠癌诊断方法。 RS15A的测定可以例如用于结肠直肠癌的早期检测或诊断。

5. 发明申请

US20090286328A1 USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER 审中-公开
标题翻译：使用蛋白S100A12作为彩色癌的标记
公开(公告)号：US20090286328A1
公开(公告)日：2009-11-19
申请号：US12264324
申请日：2008-11-04
申请人： Norbert Wild , Herbert Andres , Ursula Garczarek , Andrea Geistanger , Marie-Luise Hagmann , Johan Karl , Freidemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thiefolf
发明人： Norbert Wild , Herbert Andres , Ursula Garczarek , Andrea Geistanger , Marie-Luise Hagmann , Johan Karl , Freidemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thiefolf
IPC分类号： G01N33/566
CPC分类号： G01N33/57419 , C12Q1/6886 , G01N2333/4727 , G01N2333/805 , G01N2333/8146 , G01N2333/9121
摘要： The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的诊断。它公开了蛋白质S100A12在结肠直肠癌诊断中的应用。它涉及一种通过测量所述样品中的S100A12从粪便样品中诊断结直肠癌的方法。 S100A12的测定可以例如用于结肠直肠癌的早期检测或诊断。

6. 发明申请

US20060257951A1 Use of protein spee as a marker for breast cancer 审中-公开
标题翻译：使用蛋白质spee作为乳腺癌的标志物
公开(公告)号：US20060257951A1
公开(公告)日：2006-11-16
申请号：US11404216
申请日：2006-04-14
申请人： Gabriele Pestlin , Peter Berndt , Marie-Luise Hagmann , Johann Karl , Hanno Langen , Norbert Wild , Werner Zolg
发明人： Gabriele Pestlin , Peter Berndt , Marie-Luise Hagmann , Johann Karl , Hanno Langen , Norbert Wild , Werner Zolg
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N2333/91171
摘要： The present invention relates to the diagnosis of breast cancer. It discloses the use of spermidine synthase (SPEE) in the diagnosis of breast cancer. It relates to a method for diagnosis of breast cancer from a liquid sample, derived from an individual by measuring SPEE in the sample. Measurement of SPEE can, e.g., be used in the early detection or diagnosis of breast cancer.
摘要翻译：本发明涉及乳腺癌的诊断。它公开了亚精胺合酶（SPEE）在乳腺癌诊断中的应用。它涉及通过测量样品中的SPEE从来自个体的液体样品中诊断乳腺癌的方法。 SPEE的测量可以例如用于乳腺癌的早期检测或诊断。

7. 发明申请

US20140004544A1 FEN1 AS A MARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 审中-公开
标题翻译： FEN1作为慢性阻塞性肺疾病（COPD）的标记
公开(公告)号：US20140004544A1
公开(公告)日：2014-01-02
申请号：US14022289
申请日：2013-09-10
申请人： Johann Karl , Julia Riedlinger , Norbert Wild
发明人： Johann Karl , Julia Riedlinger , Norbert Wild
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6884 , G01N2333/914 , G01N2333/916 , G01N2800/122 , G01N2800/60
摘要： An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein FEN1 in said sample in vitro.
摘要翻译：一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。本公开还涉及通过在体外测量所述样品中的蛋白质FEN1来评估来自个体的样品的COPD的方法。

8. 发明申请

US20090075312A1 ASSESSING COLORECTAL CANCER BY MEASURING OSTEOPONTIN AND CARCINOEMBRYONIC ANTIGEN 审中-公开
标题翻译：通过测量OSTEOPONTIN和CARCINOEMBRYONIC ANTIGEN评估色素性癌
公开(公告)号：US20090075312A1
公开(公告)日：2009-03-19
申请号：US12141278
申请日：2008-06-18
申请人： Norbert Wild , Veit Peter Grunert , Johann Karl , Jarema Peter Kochan , Peter Stegmueller , Michael Tacke
发明人： Norbert Wild , Veit Peter Grunert , Johann Karl , Jarema Peter Kochan , Peter Stegmueller , Michael Tacke
IPC分类号： C12Q1/48 , G01N33/00
CPC分类号： G01N33/57419 , G01N2333/52 , G01N2333/70503
摘要： The present invention relates to a method aiding in the assessment of colorectal cancer (=CRC). It discloses the use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer. Furthermore, it especially relates to a method for assessing colorectal cancer from a liquid sample, derived from an individual by measuring at least the markers osteopontin and carcinoembryonic antigen in said sample. The marker combination comprising osteopontin and carcinoembryonic antigen can, e.g., be used in the early detection of colorectal cancer or in the surveillance of patients who undergo therapy, e.g., surgery.
摘要翻译：本发明涉及一种协助评估结肠直肠癌（= CRC）的方法。它公开了在评估结肠直肠癌中使用包含骨桥蛋白和癌胚抗原的标记物组合。此外，它特别涉及通过至少测量所述样品中的骨桥蛋白和癌胚抗原来评估来自个体的来自液体样品的结肠直肠癌的方法。包括骨桥蛋白和癌胚抗原的标记物组合可以例如用于结肠直肠癌的早期检测或用于进行例如手术治疗的患者的监视。

9. 发明授权

US07981693B2 Combined measurement of anti-CCP and serum amyloid A to assess rheumatoid arthritis 有权
标题翻译：联合测定抗CCP和血清淀粉样蛋白A以评估类风湿关节炎
公开(公告)号：US07981693B2
公开(公告)日：2011-07-19
申请号：US11509548
申请日：2006-08-24
申请人： Norbert Wild , Veit Peter Grunert , Johann Karl , Werner Zolg
发明人： Norbert Wild , Veit Peter Grunert , Johann Karl , Werner Zolg
IPC分类号： G01N33/564 , C07K14/47 , C07K16/18
CPC分类号： G01N33/564 , G01N2800/102 , G01N2800/24 , G01N2800/52
摘要： The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and serum amyloid A and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and serum amyloid A and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and serum amyloid A in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.
摘要翻译：本发明涉及一种协助评估类风湿性关节炎的方法。该方法特别用于评估体外不存在或存在类风湿性关节炎。通过分析生物化学标记可以最好地实践，包括在样品中测量抗CCP和血清淀粉样蛋白A的浓度，并将确定的浓度与不存在或存在类风湿性关节炎相关联。为了进一步改善本发明方法中RA的评估，可以与抗CCP和血清淀粉样蛋白A一起测定一种或多种另外的标记物的水平，并与RA的不存在或存在相关。本发明还涉及包含抗CCP和血清淀粉样蛋白A的标记物在诊断类风湿性关节炎中的用途，并且其教导了用于实施本发明方法的试剂盒。

10. 发明申请

US20070298518A1 Measurment of anti-CCP and serum amyloid a method to assess rheumatoid arthritis 有权
标题翻译：抗CCP和血清淀粉样蛋白的测定法评估类风湿关节炎
公开(公告)号：US20070298518A1
公开(公告)日：2007-12-27
申请号：US11509548
申请日：2006-08-24
申请人： Norbert Wild , Veit Grunert , Johann Karl , Werner Zolg
发明人： Norbert Wild , Veit Grunert , Johann Karl , Werner Zolg
IPC分类号： G01N33/564
CPC分类号： G01N33/564 , G01N2800/102 , G01N2800/24 , G01N2800/52
摘要： The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and serum amyloid A and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and serum amyloid A and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and serum amyloid A in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.
摘要翻译：本发明涉及一种协助评估类风湿性关节炎的方法。该方法特别用于评估体外不存在或存在类风湿性关节炎。通过分析生物化学标记可以最好地实践，包括在样品中测量抗CCP和血清淀粉样蛋白A的浓度，并将确定的浓度与不存在或存在类风湿性关节炎相关联。为了进一步改善本发明方法中RA的评估，可以与抗CCP和血清淀粉样蛋白A一起测定一种或多种另外的标记物的水平，并与RA的不存在或存在相关。本发明还涉及包含抗CCP和血清淀粉样蛋白A的标记物在诊断类风湿性关节炎中的用途，并且其教导了用于实施本发明方法的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式